Prospects for defined epitope vaccines for respiratory syncytial virus

Future Microbiology

Volumn 5, Issue 4, 2010, Pages 585-602

  Anderson, Robert ^a   Huang, Yan ^a   Langley, Joanne M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Vaccine enhanced RSV disease

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN F; PROTEIN G; PROTEIN L; PROTEIN M; PROTEIN M2; PROTEIN M2 1; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; MICE; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, SYNTHETIC;

MURINAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 77950514034     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.22     Document Type: Review

References (168)

1. Hall CB: Prospects for a respiratory syncytial virus vaccine. Science 265, 1393-1394 (1994). (Pubitemid 24306789)
2. Holberg CJ, Wright AL, Martinez FD et al.: Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am. J. Epidemiol. 133, 1135-1151 (1991).
3. Langley JM, LeBlanc JC, Smith B, Wang EE: Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000. J. Infect. Dis. 188, 1764-1767 (2003). (Pubitemid 38010688)
4. Parrott RH, Kim HW, Arrobio JO et al.: Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am. J. Epidemiol. 98, 289-300 (1973).
5. Ruuskanen O, Ogra PL: Respiratory syncytial virus. Curr. Prob. Pediatr. 23, 50-79 (1993). (Pubitemid 23104500)
6. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282, 1440-1446 (1999).
7. Braciale TJ: Respiratory syncytial virus and T cells: interplay between the virus and the host adaptive immune system. Proc. Am. Thor. Soc. 2, 141-146 (2005).
8. Graham BS, Rutigliano JA, Johnson TR: Respiratory syncytial virus immunobiology and pathogenesis. Virology 297, 1-7 (2002). (Pubitemid 34734904)
9. Ogra PL: Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr. Respir. Rev. 5(Suppl. A), S119-S126 (2004). (Pubitemid 38256195)
10. Openshaw PJ, Tregoning JS: Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev. 18, 541-555 (2005). (Pubitemid 40995115)
11. Peebles RS Jr: Viral infections, atopy, and asthma: is there a causal relationship? J. Allerg. Clin. Immunol. 113, S15-S18 (2004).
12. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B: Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 95, 500-505 (1995).
13. Sigurs N, Gustafsson PM, Bjarnason R et al.: Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Resp. Crit. Care Med. 171, 137-141 (2005). (Pubitemid 40105412)
14. Navas L, Wang E, de Carvalho V, Robinson J: Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J. Pediatr. 121, 348-354 (1992).
15. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ: Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr. Infect. Dis. J. 22, 483-490 (2003).
16. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL: Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98, 708-715 (1981). (Pubitemid 11070320)
17. Hall CB, Walsh EE, Long CE, Schnabel KC: Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693-698 (1991).
18. Henderson FW, Collier AM, Clyde WA Jr, Denny FW: Respiratory-syncytial- virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 300, 530-534 (1979).
19. Falsey AR, Walsh EE: Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13, 371-384 (2000). (Pubitemid 30452612)
20. Hall CB, Long CE, Schnabel KC: Respiratory syncytial virus infections in previously healthy working adults. Clin. Infect. Dis. 33, 792-796 (2001). (Pubitemid 32831835)
21. Cohen J: Bumps on the vaccine road. Science 265, 1371-1373 (1994). (Pubitemid 24306778)
22. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH: Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89, 449-463 (1969).
23. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G: Respiratory virus immunization. I. A field trial of two inactivated virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89, 435-448 (1969).
24. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE: An epidemiological study of altered clinical reactivity for respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421 (1969).
25. Kim HW, Canchola JG, Brandt CD et al.: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-433 (1969).
26. Prince GA, Jenson AB, Hemming VG et al.: Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57, 721-728 (1986).
27. Connors M, Kulkarni AB, Firestone CY et al.: Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol. 66, 7444-7451 (1992).
28. Doherty PC: Vaccines and cytokine-mediated pathology in RSV infection. Trends Microbiol. 2, 148-149 (1994). (Pubitemid 124001340)
29. Openshaw PJ, Clarke SL, Record FM: Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4, 493-500 (1992).
30. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ: Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70, 2852-2860 (1996). (Pubitemid 26121897)
31. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG: Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151, 2032-2040 (1993). (Pubitemid 23235675)
32. Hemming VG, Prince GA, Groothuis JR, Siber GR: Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8, 22-33 (1995).
33. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP: Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21, 3479-3482 (2003).
34. Shinoff JJ, O'Brien KL, Thumar B et al.: Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J. Infect. Dis. 198, 1007-1015 (2008).
35. Murphy BR, Prince GA, Walsh EE et al.: Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24, 197-202 (1986).
36. Prince GA, Curtis SJ, Yim KC, Porter DD: Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82, 2881-2888 (2001).
37. Moghaddam A, Olszewska W, Wang B et al.: A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med. 12, 905-907 (2006). (Pubitemid 44175141)
38. Polack FP, Teng MN, Collins PL et al.: A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196, 859-865 (2002).
39. Delgado MF, Coviello S, Monsalvo AC et al.: Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15, 34-41 (2009).
40. Olson MR, Varga SM: Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 182, 3024-3031 (2009).
41. Barbas CF, III, Crowe JE Jr, Cababa D et al.: Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc. Natl Acad. Sci. USA 89, 10164-10168 (1992).
42. Glezen WP, Taber LH, Frank AL, Kasel JA: Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543-546 (1986). (Pubitemid 16120909)
43. Lamprecht CL, Krause HE, Mufson MA: Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J. Infect. Dis. 134, 211-217 (1976).
44. Oien NL, Brideau RJ, Thomsen DR, Homa FL, Wathen MW: Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity. Vaccine 11, 1040-1048 (1993).
45. Walsh EE, Cote PJ, Fernie BF, Schlesinger JJ, Brandriss MW: Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J. Gen. Virol. 67, 505-513 (1986).
46. West WHL, Lounsbach GR, Bourgeois C et al.: Biological activity, binding site and affinity of monoclonal antibodies to the fusion protein of respiratory syncytial virus. J. Gen. Virol. 75, 2813-2819 (1994). (Pubitemid 24303202)
47. Li X, Sambhara S, Li CX et al.: Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 269, 54-65 (2000). (Pubitemid 30183169)
48. Wathen MW, Kakuk TJ, Brideau RJ, Hausknecht EC, Cole SL, Zaya RM: Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J. Infect. Dis. 163, 477-482 (1991).
49. Openshaw PJM: Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am. J. Resp. Crit. Care Med. 152, S59-S62 (1995).
50. Connors M, Collins PL, Firestone CY et al.: Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10, 475-484 (1992).
51. Corvaia N, Tournier P, Nguyen TN et al.: Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. J. Infect. Dis. 176, 560-569 (1997). (Pubitemid 27360518)
52. Hildreth SW, Baggs RR, Brownstein DG, Castleman WL, Paradiso PR: Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged 3-6 months after immunization. Vaccine 11, 615-618 (1993).
53. Tristram DA, Welliver RC, Hogerman DA, Hildreth SW, Paradiso P: Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: Evaluation of antibody persistence and possible disease enhancement. Vaccine 12, 551-556 (1994). (Pubitemid 24122864)
54. Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S: Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine. J. Infect. Dis. 170, 425-428 (1994). (Pubitemid 24226374)
55. Harcourt JL, Karron RA, Tripp RA: Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J. Infect. Dis. 190, 1936-1940 (2004).
56. Harris J, Werling D: Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell. Microbiol. 5, 671-680 (2003). (Pubitemid 37185044)
57. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA: Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. 77, 9831-9844 (2003). (Pubitemid 37122064)
58. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ: CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2, 732-738 (2001).
59. Kurt-Jones EA, Popova L, Kwinn L et al.: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1, 398-401 (2000).
60. Murawski MR, Bowen GN, Cerny AM et al.: Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J. Virol. 83, 1492-1500 (2009).
61. Nokes JD, Cane PA: New strategies for control of respiratory syncytial virus infection. Curr. Op. Infect. Dis. 21, 639-643 (2008).
62. Polack FP, Karron RA: The future of respiratory syncytial virus vaccine development. Pediatr. Infect. Dis. J. 23, S65-S73 (2004).
63. Schickli JH, Dubovsky F, Tang RS: Challenges in developing a pediatric RSV vaccine. Hum. Vaccin. 5, 582-591 (2009).
64. Collins PL, Murphy BR: New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc. Am. Thor. Soc. 2, 166-173 (2005).
65. Korber B, LaBute M, Yusim K: Immunoinformatics comes of age. PLoS Comput. Biol. 2, e71 (2006).
66. Reimer U: Prediction of linear B-cell epitopes. Meth. Mol. Biol. 524, 335-344 (2009).
67. Yang X, Yu X: An introduction to epitope prediction methods and software. Rev. Med. Virol. 19, 77-96 (2009).
68. Zhang Q, Wang P, Kim Y et al.: Immune epitope database analysis resource (IEDB-AR). Nucl. Acids Res. 36, W513-W518 (2008).
69. Johnstone C, de Leon P, Medina F, Melero JA, Garcia-Barreno B, Del Val M: Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus. J. Gen. Virol. 85, 3229-3238 (2004).
70. Heidema J, de Bree GJ, De Graaff PM et al.: Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J. Gen. Virol. 85, 2365-2374 (2004).
71. Tripp RA, Hou S, Etchart N et al.: CD4(+) T cell frequencies and Th1/Th2 cytokine patterns expressed in the acute and memory response to respiratory syncytial virus I-E(d)-restricted peptides. Cell. Immunol. 207, 59-71 (2001).
72. Cherrie AH, Anderson K, Wertz GW, Openshaw PJM: Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J. Virol. 66, 2102-2110 (1992).
73. Openshaw PJ, Anderson K, Wertz GW, Askonas BA: The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J. Virol. 64, 1683-1689 (1990).
74. Lukens MV, Claassen EA, de Graaff PM et al.: Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology 352, 157-168 (2006).
75. Srikiatkhachorn A, Braciale TJ: Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186, 421-432 (1997).
76. Olson MR, Hartwig SM, Varga SM: The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J. Immunol. 181, 7958-7968 (2008).
77. Olson MR, Varga SM: CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J. Immunol. 179, 5415-5424 (2007).
78. Cannon MJ, Openshaw PJM, Askonas BA: Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 168, 1163-1168 (1988).
79. Bukreyev A, Belyakov IM, Prince GA et al.: Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus. J. Virol. 79, 9515-9526 (2005).
80. Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B et al.: Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc. Natl Acad. Sci. USA 98, 9859-9864 (2001).
81. Zimmer G, Budz L, Herrler G: Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J. Biol. Chem. 276, 31642-31650 (2001).
82. Dutch RE, Jardetzky TS, Lamb RA: Virus membrane fusion proteins: biological machines that undergo a metamorphosis. Biosci. Rep. 20, 597-612 (2000).
83. Schlender J, Zimmer G, Herrler G, Conzelmann KK: Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection. J. Virol. 77, 4609-4616 (2003).
84. Nicholas JA, Rubino KL, Levely ME, Adams EG, Collins PL: Cytolytic T lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J. Virol. 64, 4232-4241 (1990).
85. Pemberton RM, Cannon MJ, Openshaw PJM, Ball LA, Wertz GW, Askonas BA: Cytotoxic T-cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J. Gen. Virol. 68, 2177-2182 (1987).
86. Chang J, Srikiatkhachorn A, Braciale TJ: Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection. J. Immunol. 167, 4254-4260 (2001).
87. Jiang S, Borthwick NJ, Morrison P, Gao GF, Steward MW: Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. J. Gen. Virol. 83, 429-438 (2002).
88. Rutigliano JA, Rock MT, Johnson AK, Crowe JE Jr, Graham BS: Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 337, 335-343 (2005).
89. Voges B, Vallbracht S, Zimmer G et al.: Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies. Cell. Immunol. 247, 85-94 (2007).
90. Johnstone C, Guil S, Rico MA et al.: Relevance of viral context and diversity of antigen-processing routes for respiratory syncytial virus cytotoxic T-lymphocyte epitopes. J. Gen. Virol. 89, 2194-2203 (2008).
91. Alwan WH, Kozlowska WJ, Openshaw PJM: Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179, 81-89 (1994).
92. Bangham CR, Openshaw PJ, Ball LA, King AM, Wertz GW, Askonas BA: Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J. Immunol. 137, 3973-3977 (1986).
93. Bukreyev A, Serra ME, Laham FR et al.: The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J. Virol. 80, 5854-5861 (2006).
94. Fan CF, Mei XG: Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response. Vaccine 23, 4453-4461 (2005).
95. Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA: Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J. Immunol. 176, 1600-1608 (2006).
96. Connors M, Kulkarni AB, Collins PL et al.: Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol. 66, 1277-1281 (1992).
97. Kulkarni AB, Collins PL, Bacik I et al.: Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J. Virol. 69, 1261-1264 (1995).
98. Vallbracht S, Jessen B, Mrusek S et al.: Influence of a single viral epitope on T cell response and disease after infection of mice with respiratory syncytial virus. J. Immunol. 179, 8264-8273 (2007).
99. Mok H, Lee S, Wright DW, Crowe JE Jr: Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope. Vaccine 26, 4775-4782 (2008).
100. Lee S, Miller SA, Wright DW, Rock MT, Crowe JE Jr: Tissue-specific regulation of CD8+ T-lymphocyte immunodominance in respiratory syncytial virus infection. J. Virol. 81, 2349-2358 (2007).
101. Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS: Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J. Virol. 83, 3019-3028 (2009).
102. Zeng R, Qi X, Gong W et al.: Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2. Vaccine 25, 7422-7428 (2007).
103. Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Illum L: Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21, 1478-1485 (2003).
104. Collins PL, Graham BS: Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 82, 2040-2055 (2008).
105. Levely ME, Bannow CA, Smith CW, Nicholas JA: Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes. J. Virol. 65, 3789-3796 (1991).
106. Castilow EM, Olson MR, Meyerholz DK, Varga SM: Differential role of g interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J. Virol. 82, 2196-2207 (2008).
107. Durbin JE, Johnson TR, Durbin RK et al.: The role of IFN in respiratory syncytial virus pathogenesis. J. Immunol. 168, 2944-2952 (2002).
108. Sparer TE, Matthews S, Hussell T et al.: Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187, 1921-1926 (1998).
109. Srikiatkhachorn A, Chang W, Braciale TJ: Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J. Virol. 73, 6590-6597 (1999).
110. Tebbey PW, Hagen M, Hancock GE: Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188, 1967-1972 (1998).
111. Varga SM, Wissinger EL, Braciale TJ: The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J. Immunol. 165, 6487-6495 (2000).
112. Hancock GE, Tebbey PW, Scheuer CA, Pryharski KS, Heers KM, LaPierre NA: Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes. J. Med. Virol. 70, 301-308 (2003).
113. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, Murphy BR: Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68, 5321-5325 (1994).
114. Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJ: Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J. Immunol. 161, 6215-6222 (1998).
115. Huang Y, Anderson R: A single amino acid substitution in a recombinant G protein vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV). Vaccine 21, 2500-2505 (2003).
116. Huang Y, Anderson R: Modulation of protective immunity, eosinophilia, and cytokine responses by selective mutagenesis of a recombinant G protein vaccine against respiratory syncytial virus. J. Virol. 79, 4527-4532 (2005).
117. Benoit AC, Huang Y, Maneewatchararangsri S, Tapchaisri P, Anderson R: Regulation of airway eosinophil and neutrophil infiltration by a-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease. Vaccine 25, 7754-7762 (2007).
118. Huang Y, Anderson R: Enhanced immune protection by a liposome- encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids from Deinococcus radiodurans. Vaccine 20, 1586-1592 (2002).
119. Mader D, Huang Y, Wang C et al.: Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge. Vaccine 18, 1110-1117 (2000).
120. Huang Y, Cyr SL, Burt DS, Anderson R: Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine. J. Clin. Virol. 44, 287-291 (2009).
121. Johnson TR, Varga SM, Braciale TJ, Graham BS: Vb14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol. 78, 8753-8760 (2004).
122. Varga SM, Wang X, Welsh RM, Braciale TJ: Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 15, 637-646 (2001). (Pubitemid 33016448)
123. Wissinger EL, Stevens WW, Varga SM, Braciale TJ: Proliferative expansion and acquisition of effector activity by memory CD4+ T cells in the lungs following pulmonary virus infection. J. Immunol. 180, 2957-2966 (2008).
124. Liu J, Ruckwardt TJ, Chen M, Johnson TR, Graham BS: Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model. J. Virol. 83, 4934-4941 (2009).
125. de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, van Lier RA: Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J. Exp. Med. 202, 1433-1442 (2005).
126. Rock MT, Crowe JE Jr: Identification of a novel human leucocyte antigen- A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. Immunology 108, 474-480 (2003).
127. Brandenburg AH, de Waal L, Timmerman HH, Hoogerhout P, de Swart RL, Osterhaus AD: HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. J. Virol. 74, 10240-10244 (2000).
128. de Waal L, Suzer Y, Wyatt LS et al.: T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells. Viral Immunol. 19, 669-678 (2006). (Pubitemid 46068060)
129. Goulder PJ, Lechner F, Klenerman P, McIntosh K, Walker BD: Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. J. Virol. 74, 7694-7697 (2000). (Pubitemid 30613121)
130. Venter M, Rock M, Puren AJ, Tiemessen CT, Crowe JE Jr: Respiratory syncytial virus nucleoprotein-specific cytotoxic T-cell epitopes in a South African population of diverse HLA types are conserved in circulating field strains. J. Virol. 77, 7319-7329 (2003). (Pubitemid 36734500)
131. Terrosi C, Di Genova G, Savellini GG, Correale P, Blardi P, Cusi MG: Immunological characterization of respiratory syncytial virus N protein epitopes recognized by human cytotoxic T lymphocytes. Viral Immunol. 20, 399-406 (2007). (Pubitemid 47585322)
132. van Bleek GM, Poelen MC, van der Most R et al.: Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells. J. Virol. 77, 980-988 (2003).
133. de Graaff PM, Heidema J, Poelen MC et al.: HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells. Virology 326, 220-230 (2004). (Pubitemid 39078254)
134. de Waal L, Yuksel S, Brandenburg AH et al.: Identification of a common HLA-DP4- restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J. Virol. 78, 1775-1781 (2004). (Pubitemid 38176709)
135. Castelli FA, Buhot C, Sanson A et al.: HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J. Immunol. 169, 6928-6934 (2002). (Pubitemid 36899279)
136. Arbiza J, Taylor G, Lopez JA et al.: Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 73, 2225-2234 (1992).
137. Lopez JA, Bustos R, Orvell C et al.: Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J. Virol. 72, 6922-6928 (1998). (Pubitemid 28324018)
138. Lopez JA, Penas C, Garcia-Barreno B, Melero JA, Portela A: Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus. J. Virol. 64, 927-930 (1990). (Pubitemid 20032714)
139. Lopez JA, Andreu D, Carreno C, Whyte P, Taylor G, Melero JA: Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein. J. Gen. Virol. 74, 2567-2577 (1993). (Pubitemid 24020648)
140. Martin-Gallardo A, Fien KA, Hu BT et al.: Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: mapping of a fusion inhibiting epitope. Virology 184, 428-432 (1991).
141. Paradiso PR, Hu BT, Arumugham R, Hildreth S: Mapping of a fusion related epitope of the respiratory syncytial virus fusion protein. Vaccine 9, 231-237 (1991).
142. Bourgeois C, Corvaisier C, Bour JB, Kohli E, Pothier P: Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus. J. Gen. Virol. 72, 1051-1058 (1991).
143. Lounsbach GR, Bourgeois C, West WHL, Robinson JW, Carter MJ, Toms GL: Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli. J. Gen. Virol. 74, 2559-2565 (1993). (Pubitemid 24020647)
144. Trudel M, Nadon F, Seguin C, Dionne G, Lacroix M: Identification of a synthetic peptide as part of a major neutralization epitope of respiratory syncytial virus. J. Gen. Virol. 68, 2273-2280 (1987). (Pubitemid 17122710)
145. Langedijk JP, Meloen RH, van Oirschot JT: Identification of a conserved neutralization site in the first heptad repeat of the fusion protein of respiratory syncytial virus. Arch. Virol. 143, 313-320 (1998).
146. Crowe JE, Firestone CY, Crim R et al.: Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology 252, 373-375 (1998). (Pubitemid 29013419)
147. Singh SR, Dennis VA, Carter CL, Pillai SR, Moore EG: Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice. Viral Immunol. 20, 261-275 (2007).
148. Singh SR, Dennis VA, Carter CL et al.: Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 25, 6211-6223 (2007).
149. Wu SJ, Schmidt A, Beil EJ et al.: Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. J. Gen. Virol. 88, 2719-2723 (2007).
150. Murata Y, Lightfoote PM, Rose RC, Walsh EE: Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol. J. 6, 81 (2009).
151. Sakurai H, Williamson RA, Crowe JE et al.: Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J. Virol. 73, 2956-2962 (1999). (Pubitemid 29135684)
152. Scopes GE, Watt PJ, Lambden PR: Identification of a linear epitope on the fusion glycoprotein of respiratory syncytial virus. J. Gen. Virol. 71, 53-59 (1990). (Pubitemid 20046009)
153. Chargelegue D, Obeid OE, Hsu SC et al.: A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo. J. Virol. 72, 2040-2046 (1998). (Pubitemid 28100758)
154. Hsu SC, Chargelegue D, Obeid OE, Steward MW: Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. J. Gen. Virol. 80, 1401-1405 (1999).
155. Beeler JA, Van Wyke Coelingh K: Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63, 2941-2950 (1989).
156. Zhao X, Chen FP, Megaw AG, Sullender WM: Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J. Infect. Dis. 190, 1941-1946 (2004). (Pubitemid 39564699)
157. Zhao X, Chen FP, Sullender WM: Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318, 608-612 (2004).
158. Johnson S, Oliver C, Prince GA et al.: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215-1224 (1997).
159. DeVincenzo JP, Hall CB, Kimberlin DW et al.: Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J. Infect. Dis. 190, 975-978 (2004).
160. Ulbrandt ND, Ji H, Patel NK et al.: Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. J. Gen. Virol. 89, 3113-3118 (2008).
161. Weisman LE: Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. Curr. Op. Mol. Ther. 11, 208-218 (2009).
162. Wu H, Pfarr DS, Johnson S et al.: Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652-665 (2007).
163. Garcia-Barreno B, Delgado T, Akerlind-Stopner B, Norrby E, Melero JA: Location of the epitope recognized by monoclonal antibody 63G on the primary structure of human respiratory syncytial virus G glycoprotein and the ability of synthetic peptides containing this epitope to induce neutralizing antibodies. J. Gen. Virol. 73, 2625-2630 (1992).
164. Simard C, Nadon F, Seguin C et al.: Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174-187 from the G glycoprotein: the role of cysteinyl residues in protection. Vaccine 15, 423-432 (1997).
165. Walsh EE, Falsey AR, Sullender WM: Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein. J. Gen. Virol. 79, 479-487 (1998).
166. Plotnicky-Gilquin H, Goetsch L, Huss T et al.: Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J. Virol. 73, 5637-5645 (1999).
167. Feldman SA, Hendry RM, Beeler JA: Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J. Virol. 73, 6610-6617 (1999).
168. Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ: Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein. J. Biol. Chem. 276, 38988-38994 (2001).